Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)

Digestion

Volumn 57, Issue 6, 1996, Pages 478-483

  Goldberg, Paul A ^a   Kamm, Michael A ^a   Setti Carraro, Paulo ^a   van der Sijp, Joost R M ^a   Christian, Roth ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

5 HT3 antagonism; Irritable bowel syndrome; Pain; Visceral sensitivity

Indexed keywords

ONDANSETRON; SEROTONIN; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELASTICITY; ELECTROSTIMULATION; FECES; FEMALE; GASTROINTESTINAL MOTILITY; HUMAN; HUMAN EXPERIMENT; INTESTINE FUNCTION; IRRITABLE COLON; MALE; MANOMETRY; NERVE CELL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PAIN; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; SYMPTOM; VISCERA;

ADULT; ANAL CANAL; COLONIC DISEASES, FUNCTIONAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTRIC STIMULATION; FEMALE; HUMANS; MALE; MANOMETRY; MIDDLE AGED; ONDANSETRON; PAIN; PRESSURE; RECTUM; SENSATION; SEROTONIN ANTAGONISTS;

EID: 0029848204     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201377     Document Type: Article

References (28)

1. Bazzocchi G, Ellis J, Villanucva-Mcycr J, Reddy SN, Mena I, Snape WJ Jr.: Effect of eating on colonic motility and transit in patients with functional diarrhea, Simultaneous scintigraphic and manometric evaluations. Gastroenterology 1991;101:1298-1306.
2. Rogers J, Henry MM, Misiewicz JJ: Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989:30:634-641.
3. Kumar D, Wingate DL: The irritable bowel syndrome: A paroxvsmal motor disorder. Lancet 1985;2:973-977.
4. Kellow JE, Phillips SF: Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987: 92:1885-1893.
5. Ritchie J: Pain from distension of the pelvic colon by inflating a balloon in the irritable bowel syndrome. Gut 1973:14:125-132.
6. Whitehead WE, Engel BT, Schuster MM: Irritable bowel syndrome, Physiological and psychological differences between diarrhoea-prc-dominate and constipation-predominant patients. DigSci 1980:25:404-413.
7. Prior A, Maxton DG, Whorwcll PJ: Anorectal manometry in irritable bowel syndrome: Differences between diarrhoea and constipation predominant subjects. Gut 1990:31:458-462. Cook 1J, Van Eeden A, Collins SM: Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987:93:727-733.
8. Kellow JE, Eckcrslcy CM, Jones MP: Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991:101:1621 -1627.
9. Klein KB: Controlled treatment trials in irritable bowel syndrome: A critique. Gastroenterology 1988:95:232-241.
10. Talley NJ, Turner I, Middleton WR: Somatostatin and symptomatic relief of irritable bowel. Lancet 1987;2:1114.
11. Bradette M, Staumont G, Delvaux M, Fiora-monti J, Bueno L, Frexinos J: The somatostatin analogue octreotide increases thresholds of discomfort and pain perception to colonic distension in irritable bowel syndrome patients (abstract). Gastroenterology 1993;104:A482.
12. Gershon MD: Enteric nervous system: Neural connections, neurotransmitters, and the function of 5-hvdroxytryptamine: in Kamrn MA, Lennard-Jones JE (eds): Gastrointestinal Transit - Pathophysiology and Pharmacology, Petersfield, Wrightson Biomedical Publishing, 1991, pp 21-32.
13. Farthing MJ: 5-Hydroxytryptaminc and 5-hv-droxytryptaminc-3 receptor antagonists. Scand J Gastroenterol 1991;26(suppl 188):92-100.
14. Talley NJ: Review article: 5-Hydroxytrypta-mine agonists and antagonists in the modulation of gastrointestinal motility and sensation: Clinical implications. Aliment Pharmacol Ther 1992:6:273-289.
15. Costall B, Naylor RJ: 5-Hydroxytryptamine: New receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 1990:25:769-787.
16. Nemeth PR, Gullikson GW: Gastrointestinal motility stimulating drugs and 5-HT receptors on myenteric neurons. Eur J Pharmacol 1989: 166:387-391.
17. Richardson BP, Engel G, Donatscn P, Stadler PA: Identification of serotonin M-reccptor sub-types and their specific blockade by a new class of drugs. Nature 1985:316:126-131.
18. Moss HE, Sanger GJ: Antagonism by BRL43694A of pseudo-affective reflex induced by duodenal distension (abstract). Br J Pharmacol 1987:92:53
19. Richardson BP, Engel G: The pharmacology and function of 5HT, receptors. Trends Neu-rosci 1986:424-428.
20. Slacker G, Gaupmann G, Schneider C, Stach-er-Janotta G, Steincr-Mittelbach G, Abatzi THA, Steinringer H: Effects of a 5-hydroxy-tryptaminc, receptor antagonist (ICS 205-930) on colonic motor activity in healthy men. Br J Clin Pharmacol 1989:28:315-322.
21. Prior A, Read NW: Reduction of rectal sensitivity and post-prandial motility by granisc-tron, a 5-HT,-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993:7:175-180.
22. Rogers J, Laurbcrg S, Misiewicz JJ, Henry MM, Swash M: Anorectal physiology validated: A repeatability study of the motor and sensory tests of anorectal function. Br J Surg 1989;76:607-609.
23. Speakntan CT, Kamm MA: Abnormal visceral autonomic innervation in neurogenic faecal incontinence. Gut 1993:34:215-221.
24. Kamm MA, Lennard-Jones JE: Rectal mucosal electrosensory testing - Evidence for a rectal sensory neuropathy in idiopathic constipation. Dis Colon Rectum 1990;33:419-423.
25. Steadman CJ, Talley NJ, Phillips SF, Zins-meislcr AR: Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: A pilot study. Mayo Clin Proc 1992;67:732-738.
26. Maxton DG, Haigh CG, Whorwell PJ: 5-HT, antagonism: A role in irritable bowel syndrome and non-ulcer dyspepsia? (abstract). Gut 1991: 32:A1228.
27. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE: Efficacy of oral ondansetron in the prevention of emcsis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993:118:407-413.
28. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdalc II, Morris AI: Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990:4: 139-144